2,5-二氟苯甲酸甲酯 | 362601-90-9

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,5-二氟苯甲酸甲酯
• 英文名称: methyl 2,5-difluorobenzoate
• CAS: 362601-90-9
• 化学式: C₈H₆F₂O₂
• mdl: MFCD03093800
• 分子量: 172.131
• InChiKey: UDBLTZWJCWPYBA-UHFFFAOYSA-N

物化性质

• 沸点：
  204-205 °C (lit.)
• 密度：
  1.265 g/mL at 25 °C (lit.)
• 闪点：
  180 °F
• 保留指数：
  1110

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn,Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R22,R41,R37/38
• WGK Germany：
  3
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 2,5-difluorobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2,5-difluorobenzoate
CAS number: 362601-90-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6F2O2
Molecular weight: 172.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二氟苯甲酸甲酯 在 sodium ethanolate 、 甲基三苯基溴化膦 、 sodium hydride 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 1.0h， 生成 艾沙康唑中间体7
  参考文献：
  名称：

  一种艾沙康唑中间体的制备方法

  摘要：

  本发明属于化学药物中间体的制备技术领域，具体涉及一种艾沙康唑中间体的制备方法，即4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三氮唑-1-基)丁烷-2-基)噻唑-4-基)苯腈的制备方法。其结构式(式1)如下：

  公开号：

  CN105732605A
• 作为产物：
  描述：

  5-Chlor-2,3,4,6-tetrafluor-benzoesaeure-methylester 在 fac-tris(2-phenylpyridinato-N,C2')iridium(III) 、 N,N-二异丙基乙胺 作用下， 以 氘代苯 、 乙腈 为溶剂， 以78 %的产率得到2,5-二氟苯甲酸甲酯
  参考文献：
  名称：

  分子雕刻：通过苯甲酸盐的光催化加氢脱氟加快获得各种氟化芳烃的多用途工具

  摘要：

  从高度氟化的苯甲酸酯开始，我们开发了氟化苯甲酸芳基酯的定向光催化加氢脱氟 (HDF)，并展示了它与其他 HDF 策略的协同作用，以及 C-H 芳基化、脱羧偶联和脱羧质子化，以获得大多数氟化模式苯甲酸酯衍生物，并通过分子雕刻方法扩展苯衍生物。温和的反应条件和出色的区域选择性使该方法成为合成的理想选择。这种方法提供了从几种高度氟化的市售苯甲酸中获得 16 种具有不同氟化模式的苯甲酸酯衍生物的途径。我们为西格列汀、二氟尼柳和其他药学上重要的分子合成关键中间体或活性药物成分。重要的，我们提供了关于相对脱氟率和改变这些率的策略的重要见解。我们展示了 HDF 和相关技术的协同使用，以快速提高这些简单的商用全氟芳烃的合成复杂性，从而形成复杂的部分氟化分子。

  DOI：

  10.1021/acs.joc.2c02332

文献信息

• [EN] POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER<br/>[FR] AMIDES POLYCYCLIQUES UTILISÉS EN TANT QUE MODULATEURS D'UBE2K POUR LE TRAITEMENT DU CANCER
  申请人：BERG LLC

  公开号：WO2021138540A1

  公开（公告）日：2021-07-08

  Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

  提供的是Formula (I)的化合物及其药用盐和组合物，可用于治疗与UBE2K调节相关的疾病。
• [EN] HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES DES PROTÉINES DU NOYAU DE L'HÉPATITE B
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2015138895A1

  公开（公告）日：2015-09-17

  ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

  摘要 本公开提供了部分具有对乙型肝炎病毒Cp具有变构效应的化合物。本文还提供了治疗病毒感染（如乙型肝炎）的方法，包括向需要的患者施用所述化合物。
• DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424
  申请人：Brown Dean

  公开号：US20090318415A1

  公开（公告）日：2009-12-24

  Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.

  合成以下公式：其中Z如规范中所述，其药学上可接受的盐，包含相同物质的组合物，以及使用该化合物治疗双相情感障碍、焦虑障碍、情绪障碍或精神分裂症或其他精神障碍的方法。
• [EN] INHIBITORS OF THE MENIN-MLL INTERACTION<br/>[FR] INHIBITEURS DE L'INTERACTION MÉNINE-MLL
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2018053267A1

  公开（公告）日：2018-03-22

  The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

  本发明涉及抑制menin与MLL及MLL融合蛋白相互作用的抑制剂，含有这些抑制剂的药物组合物，以及它们在治疗由menin-MLL相互作用介导的癌症和其他疾病中的应用。
• [EN] BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLYLES BICYCLIQUES COMME INHIBITEURS DE IRAK4
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2015104688A1

  公开（公告）日：2015-07-16

  The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, 'm', 'n' and 'p' have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式（I）的双环杂环基激酶酶抑制剂化合物，其作为激酶抑制剂在治疗上具有疗效，特别是IRAK4抑制剂。其中A、Y、Z、X1、X2、X3、R1、R3、'm'、'n'和'p'在规范中给出了含义，并且具有治疗和预防疾病或疾病的药用盐或其立体异构体，在特定情况下用于由激酶酶介导的疾病或疾病的治疗。本发明还提供了包括至少一种式（I）化合物的药物组合物，与药用载体、稀释剂或赋形剂一起。